

# Beta-Lactamase Encoded Genes bla<sub>TEM</sub> and bla<sub>CTX</sub> Among *Acinetobacter baumannii* Species Isolated From Medical Devices of Intensive Care Units in Tehran Hospitals

Sara Khalilzadegan,<sup>1</sup> Mojtaba Sade,<sup>2,\*</sup> Hussein Godarzi,<sup>3</sup> Gita Eslami,<sup>3</sup> Masoumeh Hallajzade,<sup>3</sup> Fatemeh Fallah,<sup>3</sup> and Davood Yadegarnia<sup>4</sup>

<sup>1</sup>Department of Microbiology, Guilan Science and Research Branch, Islamic Azad University, Rasht, IR Iran

<sup>2</sup>International Branch, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

<sup>3</sup>Microbiology Group, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

<sup>4</sup>Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

\*Corresponding author: Mojtaba Sade, International Branch, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-2165352504, Fax: +98-2165352503, E-mail: msade110@gmail.com

Received 2013 October 20; Revised 2015 August 03; Accepted 2015 September 26.

## Abstract

**Background:** Excessive consumption of antimicrobial materials in hospitals is considered as the main encoder leading to the emergence, development and acquisition of new bacterial resistance to beta-lactamase.

**Objectives:** Owing to the lack of proper information regarding the mechanism of the bacterial resistance to antibiotics and responsible genes in the country, the current study aimed to consider the resistance or sensitivity of the *Acinetobacter baumannii* multi drug resistant (MDR) isolates facing 2% glutaraldehyde. The study was conducted in the selected intensive care units in Tehran hospitals, Iran, in 2013.

**Materials and Methods:** In this study conducted over a period of 10 months, *A. baumannii* species were isolated by bacterial culture following biochemical tests from intensive care units (ICUs) of some hospitals in Tehran, Iran (Fayazbaksh, Taleghani, Imam Khomeini, Valiasr, Labafinejad). The resistance and sensitivity of the isolates to antibiotics were considered according to the clinical and laboratory standard institute CLSI (2012) guidelines. By multiplex PCR method, bla<sub>CTX</sub> and bla<sub>TEM</sub> genes were detected and finally, MDR strains were treated with 2% glutaraldehyde. PCR was used for each strain of MDR using specific primers.

**Results:** In the current study, 131 *A. baumannii* isolates (22.3%) out of 588 were studied. The level of resistance to various antibiotics was in the range of 69.4% to 100%. The frequencies of bla<sub>TEM</sub> and bla<sub>CTX</sub> genes were 3.2% and 19.4%, respectively. MIC<sub>50</sub> and MIC<sub>90</sub> of imipenem and meropenem antibiotics were 32 ± 1 µg/mL and 64 ± 1 µg/mL, respectively (P < 0.9). However no resistance to glutaraldehyde was observed. Different bands of MDR strains were observed in the PCR product by electrophoresis.

**Conclusions:** It seems that besides the variety and prevalence of bla<sub>TEM</sub> and bla<sub>CTX</sub>, enormous mechanisms such as porin and leaking systems (efflux pumps) are responsible for the information of the *A. baumannii* resistance to disinfectants. The study on an accurate consideration of the resistance in strains and other microorganisms is advised.

**Keywords:** Lactamase Genes, Antimicrobial Resistance, Disinfectants, *Acinetobacter baumannii*

## 1. Background

Excessive and improper use of antimicrobials (antibiotics and biocide) in hospitals and community has led to development and acquisition of bacterial resistance to antimicrobials (1). These factors can transfer within mobile genetic elements such as conjugative plasmids, transposon, integron and chromosomes (2, 3). Resistance to a wide range of antimicrobial agents and emergence of MDR, extreme drug resistant (XDR) and pan drug resistant (PDR) phenotypes between some nosocomial infectious agents such *Acinetobacter* species in some countries especially in Iran has increased (4-6) During the last three decades, *Acinetobacter* species are detected accompanied by beta-

lactamase encoded enzymes, bla<sub>TEM</sub>, bla<sub>CTX</sub> and New-Delhe-metallo-B-lactamase-1 from a wide variety of environments (7).

Also the presence of OXA-48, OXA-181, CTX-M-15, SHV, bla<sub>OXA</sub>-23,24,51, bla<sub>CTX</sub> (oxA-10,2), TEM (bla<sub>TEM</sub>-1,2,13), methylase, ESBL, qnr and six types of NDM<sub>5</sub> (1-2-3-4-5-6), disinfectant resistance genes, qac (A-E) (8) and detection of new plasmids such as PNDm-1-DOK01 encoding different types of outer membrane proteins (OMPA), siderophores and iron acquisition systems (9), presence of pili mediated DNA uptake and biofilm formation by fimbria and exopolysaccharides on biotic and abiotic surfaces convert the *Acinetobacter baumannii* to a super bug (10, 11). Authors were eager to study *A. baumannii* isolates collected

from hospital ICU environments and medical equipment surfaces in Tehran. The frequency of bla<sub>TEM</sub> and bla<sub>CTX</sub> resistance genes was evaluated by molecular techniques among the isolates. In the next step, the susceptibility of *A. baumannii* isolates to 2% glutaraldehyde solution was determined.

## 2. Objectives

The current study aimed to investigate the responsible genes and mechanism of resistance and sensitivity of *Acinetobacter* species to 2% glutaraldehyde in order to design protective schemes such as controlling infection in hospital and precise determination of phenotype and genotype resistance patterns for MDR species.

## 3. Materials and Methods

### 3.1. Bacterial Isolates and Identification

The current experimental analysis collected 588 samples from surfaces of medical equipment of ICUs of different hospitals in Tehran from January 2013 to November 2013 by standard sampling methods including swabs and transport medium Tryptic soy broth (MERCK, Germany). One hundred-thirty-one samples of *A. baumannii* were biochemically identified as explained in Table 1.

**Table 1.** Identification of *Acinetobacter* Species<sup>a</sup>

Test	Reaction
Oxidase	-
KIA	K/K
TSI	K/K
Growth on MAC	+
Motility	-
OF-glucose	+
OF-lactose	+
Urea	-
Growth at 42°C	+
Nitrate	-
Hemolysis	-
Arginine	-
Malonate	+
Gelatin hydrolysis	-

<sup>a</sup>Definitions: +, means growth; -, means no growth.

Antibiotic disks used in the study were imipenem (10 µg), meropenem (10 µg), ceftizoxime (30 µg), oxacillin

(1 µg), gentamicin (10 µg) and lincomycin (2 µg) ciprofloxacin (5 µg), ceftazidime (30 µg), cefotaxime (30 µg), ampicillin (10 µg), tetracycline (30 µg), cefixime (5 µg) and colistin (10 µg) collected from (Mast Diagnostics, Mast group Ltd., Mersey side, UK). The level of sensitivity or resistance of the isolates to antibiotics were measured by disk diffusion method and the minimum inhibitory concentration (MIC) of MDR strains to imipenem and meropenem antibiotics was measured by microdilution method (12). The responsible genes to detect beta-lactamases (bla<sub>TEM</sub> and bla<sub>CTX</sub>) were detected in resistant isolates according to their appearance on the electrophoresis bands.

### 3.2. Amplification of bla<sub>TEM</sub> and bla<sub>CTX</sub>-M Genes by PCR Method

Boiling method was used to extract DNA of *A. baumannii* MDR isolates. The isolated DNA with specific primers for the study was confirmed by BLAST bank, and bla<sub>TEM</sub> and bla<sub>CTX</sub> were detected by PCR. The PCR primers used to amplify bla<sub>TEM</sub>, bla<sub>CTX</sub> genes in the study are shown in Table 2. The PCR mix consisted of 25 µL containing 7.5 µL distilled water, 12.5 µL 10X PCR master mix (Fermentas Company, Burlington, Ontario, Canada) and 3 µL of DNA template; 1 µL of each forward and reverse primers of the genes TEM and CTX in 10 pmol concentration were used. The primer sequences are summarized in Table 2. The temperature gradient and the temperature of annealing for both genes were 54°C. To reassure the accuracy of the test and considering reversibility of the results, PCR levels were performed twice for each and every one of the MDR strains. To sequence the TEM, CTX genes <http://www.lahcy.orgs> site (13) was used. PCR conditions genes are summarized in Table 3.

**Table 2.** Primer Sequences and Length of Amplification Products

Genes	Primer Sequences (5' - 3')	Product Sizes, bp
Bla <sub>CTX-A</sub>	5'-CGCTTTGCGATGTGCAG-3'	550
Bla <sub>CTX-B</sub>	5'-ACCGCGATATCGTTGGT-3'	550
Bla <sub>TEM-A</sub>	5'-GAGTATTCAACATTTCCGTGTC-3'	800
Bla <sub>TEM-B</sub>	5'-TAATCAGTGAGGCACCTATCTC-3'	800

### 3.3. Electrophoresis

The PCR products were screened by agarose gel electrophoresis method on 1.5% agarose (Ultrapure™ Invitrogen, CA, USA). Electrophoresis was performed by 90 A voltage in 60 minutes (14). Amplified genes were separated according to their molecular size. The product were stained by ethidium bromide (0.5 g/mL) and then washed with distilled water twice. Finally the stained gels were monitored

**Table 3.** PCR Conditions Genes<sup>a</sup>

Step	Temp, °C		Time	
	CTX	TEM	CTX	TEM
Initial denaturation of heat shock	94	94	3 min	3 min
DNA denaturation	94	94	30 s	30 s
Primer annealing pairing	63	45	1min	1 min
Primer extension / elongation	72	72	1 min	1 min
Final extension/ final elongation	72	72	10 min	10 min

<sup>a</sup>Number of the PCR cycles = 35.

by gel documentation system (T. N.) and the corresponding images were taken and analyzed for their associated bounds accordingly to detect the location and size of the DNA of the goal genes GenRuler™ 1 kb DNA ladder, ready-to-use (Fermentas Company, Burlington, Ontario, Canada) was used (Figures 1 and 2). The data were analyzed by SPSS statistical software and t-test was used to analyze antibiotic resistance and the product of the bla<sub>TEM</sub> and bla<sub>CTX</sub> genes.

### 3.4. Treating 2% Glutaraldehyde With MDR Strains

Bacterial suspension perpetrated by direct colony suspension method (DCS) based on McFarland 0.5 standards. The suspension exposure to 2% glutaraldehyde (neodish-ersepto 3000 according to EC with the number 20048164) at 5, 10 and 15 minutes, stops the growth of MRD bacteria in the suspension. Shorter exposures had no impact on the bacteria.

The suspensions were cultured on blood agar and incubated for 16 - 18 hours at 37°C. The growth of the resistant isolates was considered after 18 hours. Then 2% sodium hydroxide was added to neutralize glutaraldehyde which raised the pH to 12; to back the suspension to the neutralized pH, some acids such as hydrochloric acid was used. By adding sterile PBS, the solutions were washed and again cultured on blood agar plates and incubated for 16 - 18 hours at 37°C. The growth of the resistant isolates was considered after 18 hours again. At this level, a specific volume of microbial suspension (tied to McFarland 0.5) was spread on some surfaces with the dimensions of 25 cm<sup>2</sup> and immediately the 2% glutaraldehyde was added and 5, 10 and 15 minutes after the exposure, sampling was performed using standard and sterile swaps; samples were cultured on blood agar and incubated for 16 - 18 hours at 37°C.

## 4. Results

In the current study 131 *A. baumannii* (22.3%) were isolated out of 588 samples. The minimum and maximum

average frequencies of the MDR strains in the ICUs were 21% and 24%, respectively. The most frequent MDR strains were isolated from ICU II of Fayazbakhsh hospital (22.8%) and the least was found in ICU and NICU of Taleghani hospital (21.3%). Antimicrobial resistance ranges are shown in Table 4. MIC<sub>50</sub> and MIC<sub>90</sub> of imipenem and meropenem were 32 ± 1 and 64 ± 1 µg/mL respectively (P < 0.9) (Table 5). The results of the amplification were confirmed by PCR method (Figures 1 and 2).


**Table 4.** Antimicrobial Resistance of Clinical Isolates of *Acinetobacter baumannii*

Antimicrobial Resistance Trait	No. (%) of Isolates
Imipenem (10 µg)	100
Meropenem (10 µg)	100
Lincomycin (2 µg)	100
Ceftazidime (30 µg)	99
Ciprofloxacin (30 µg)	98
Oxacillin (1 µg)	90
Ceftizoxime (30 µg)	90
Gentamicin (10 µg)	85.97
Tetracycline (30 µg)	70.2
Ampicillin (10 µg)	70.2
Cefotaxime (30 µg)	69.4
Cefixime (5 µg)	69.4

### 4.1. Evaluation of Treating 2% Glutaraldehyde on Resistant Isolates


The previous data recommended that the 2% glutaraldehyde disinfectants at least in 10 or 15 minutes have inhibitory effect on the growth of *A. baumannii* suspension equivalent to McFarland 0.5 standard. In the current experiment longer and shorter exposure times were also evaluated. The results indicated that 5 minutes (the shorter rec-

Figure 1. Gel Electrophoresis of bla<sub>CTX</sub> Gene in *Acinetobacter baumannii* Strains Isolated From Hospital Surfaces and Equipment



N, number of template DNA; M, size marker 1 kb ladder.

Figure 2. Gel Electrophoresis of *Acinetobacter baumannii* bla<sub>TEM</sub> Gene



N, number of template DNA; M, size marker 1 kb ladder.

ommended time) exposure to 2% glutaraldehyde disinfectant had no inhibitory effect on the bacterial growth.

The current study demonstrated that, through various mechanisms such as linking with non-protein amines in the level of bacterial cell, hydroxyl and amine in microorganisms, cross linking with alpha amino acid amine lysine and other amino acids and preventing the transmission and activation of dehydrogenized elements, glutaraldehyde can be applied as a disinfectant to sterilize and

disinfect surfaces and medical equipment in the special care wards of hospitals.

### 5. Discussion

Multi drug resistance in *A. baumannii* is considered as the major cause of the failure of nosocomial infections treatment. Because of spontaneous resistance and adaptation of the genetic elements which carry resistance genes,

**Table 5.** Minimum Inhibitory Concentration of Meropenem and Imipenem on *Acinetobacter baumannii*

Antibiotic	<i>Acinetobacter baumannii</i> , µg/mL		
	MIC50% <sup>a</sup>	MIC90% <sup>a</sup>	MIC Range
Imipenem	32 ± 1	64 ± 1	4 - 128
Meropenem	32 ± 1	64 ± 1	4 - 128

<sup>a</sup>Values are expressed as mean ± SD.

and also acquisition of enzymatic and non-enzymatic resistance genes, facing antibiotics and biocides and by the emergence of PDR, XDR, MDR phenotypes, global health concerns are raised. However, *A. baumannii* antibiotic resistance due to defects or reduction in expression of outer membrane proteins such as porins, presence of leakage system (efflux pumps) (15), mutations in topoisomerase, occurrence of resistance-nodulation cell division (RND) and toxic compound extrusion are considered as some of the resistance mechanisms (16, 17). In the previous studies, the frequencies of multidrug-resistant *A. baumannii* species were reported as 30 - 89% in the world.

Ferreira et al. found that 68% of the bacterial isolates in Brazil were multidrug resistant (18). In Greece, the number of *A. baumannii* MDR phenotype was reported 83.9%. Peymani et al. in Tabriz found that 80% of the isolates were multidrug resistant (19). Based on the study of Ghalavand in Tehran, the frequency of MDR and XDR isolates of *A. baumannii* were 83% and 44.8%, respectively. In the current study 87.3% of the isolates were multidrug resistant, similar to the previous findings. No resistance to colistin was reported in Iran which corresponded to the reports from different parts of the world.

In Ghalavand's study, the rate of resistance to carbapenems was 92%. In the present study all *A. baumannii* isolates (100%) were resistant to carbapenems which compared to other previous data were the high incidence of carbapenem resistance in *A. baumannii* isolates. Ghalavand et al. reported the incidence of resistance to meropenem, ciprofloxacin and cefepime in *A. baumannii* isolates as 99%, 98% and 90% respectively which were similar to the current study results and those of Faizabady's; it was in contrast with the study by Hujer et al. in U.S.A which the rate of resistance to meropenem and imipenem were reported more than 90% (20, 21). According to the current study results, the frequency of imipenem-meropenem resistant *A. baumannii* was in contrast with the results of world researches.

The high rates of resistance are related to excessive and improper use of antimicrobials in the ICUs in Iran. Hujer research reported that 40% of the isolates carried bla<sub>CTX</sub>

and 12.8% carried bla<sub>TEM</sub> (21). On the other hand, multi drug efflux pumps play an important role in the appearance of resistant strains to some drugs because of sobestrical wide variety, side effects of the increase in statements and abundance of the efflux pumps which results in boosting and leaking of a huge range of antimicrobials, antiseptic, colors, detergents and disinfections. Making some new drugs to cope multi-drug resistance is the new goal in medical treatments. Moreover, phenotype test shows that 131 isolates of *Acinetobacter* species, carrying bla<sub>CTX</sub> (19.4%) and bla<sub>TEM</sub> (3.2%) genes which confirms that the resistant to glutaraldehyde is significant. PCR is known as a sensitive and effective method for epidemiological analysis and tracing MDR, XDR and PDR species.

This study showed that 2% glutaraldehyde is an effective disinfectant to sterile surfaces and medical equipment of ICUs. This compound has different mechanisms such as linking with non-protein amines of bacteria cell, cross linking with alpha amino acid, amine (lysine) and other amino acids, preventing transfer, dehydrogenating and interaction. It can also, to a lower extent, react with lipase, carbohydrates and nucleotidases. Due to the fact that proteins are universal compound in cells, glutaraldehyde is capable to link cellular compounds. Presence of MDR species necessitates the use of 2% glutaraldehyde, washing hands and maintaining hygiene in hospitals.

The results of this study showed that the genetic patterns of particular genes bla<sub>TEM</sub> and bla<sub>CTX</sub> in *A. baumannii* isolates have wide diversity Hence evaluation of new antibacterial and disinfectant agents, efficacy, and proper management of antimicrobial agents can control *A. baumannii* infection and prevent appearance of resistant strains in the hospitals and community. Also conducting more precise and comprehensive study on phenotypic and genotypic resistance patterns of *A. baumannii* against different classes of antibiotics and disinfectant agents is recommended.

## Acknowledgments

Authors of the current study wish to thank the staff of research laboratory of medical microbiology faculty and Imam Khomeini, Vali-e-Asr, Labbafinejad, Fayazbakhsh and Taleghani hospitals for their assistance.

## Footnotes

**Authors' Contribution:** Sara Khalilzadegan, Mojtaba Sade, Hussein Godarzi, Gita Eslami, Masoumeh Hallajzade, Fatemeh Fallah, and Davood Yadegarnia equally participated in the study.



**Funding/Support:** This study was financially supported by Shahid Beheshti University, Tehran, Iran; department of microbiology, Guilan science and research branch Islamic Azad University provided the laboratory facilities.

## References

- Lacey RW. Antibiotic resistance in *Staphylococcus aureus* and streptococci. *Br Med Bull*. 1984;**40**(1):77-83. [PubMed: 6442875].
- Issa NC, Thompson RL. Staphylococcal toxic shock syndrome. Suspicion and prevention are keys to control. *Postgrad Med*. 2001;**110**(4):55-6. [PubMed: 11675982].
- Naidoo J. Interspecific co-transfer of antibiotic resistance plasmids in staphylococci in vivo. *J Hyg (Lond)*. 1984;**93**(1):59-66. [PubMed: 6747287].
- Sabath LD, Wheeler N, Laverdiere M, Blazevic D, Wilkinson BJ. A new type of penicillin resistance of *Staphylococcus aureus*. *Lancet*. 1977;**1**(8009):443-7. [PubMed: 65561].
- Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY. Emergence and spread of multi-drug resistant organisms: think globally and act locally. *J Microbiol Immunol Infect*. 2011;**44**(3):157-65. doi: 10.1016/j.jmii.2011.03.001. [PubMed: 21524608].
- Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in *Acinetobacter baumannii*: the molecular epidemic features of an emerging problem in health care facilities. *J Infect Dev Ctries*. 2009;**3**(5):335-41. [PubMed: 19759502].
- Gouby A, Carles-Nurit MJ, Bouziges N, Bourg G, Mesnard R, Bouvet PJ. Use of pulsed-field gel electrophoresis for investigation of hospital outbreaks of *Acinetobacter baumannii*. *J Clin Microbiol*. 1992;**30**(6):1588-91. [PubMed: 1352519].
- Johnston LH, Dyke KG. Ethidium bromide resistance, a new marker on the staphylococcal penicillinase plasmid. *J Bacteriol*. 1969;**100**(3):1413-4. [PubMed: 5361223].
- Lankford CE, Byers BR. Bacterial assimilation of iron. *CRC Crit Rev Microbiol*. 1973;**2**(3):273-331. doi: 10.3109/10408417309108388.
- Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis*. 2011;**17**(10):1791-8. doi: 10.3201/eid1710.110655. [PubMed: 22000347].
- Chen Y, Cui Y, Pu F, Jiang G, Zhao X, Yuan Y, et al. Draft genome sequence of an *Acinetobacter* genomic species 3 strain harboring a bla(NDM-1) gene. *J Bacteriol*. 2012;**194**(1):204-5. doi: 10.1128/JB.06202-11. [PubMed: 22156399].
- Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant *Acinetobacter baumannii*. *Clin Microbiol Infect*. 2000;**6**(12):635-43. [PubMed: 11284921].
- Seifert H, Gerner-Smidt P. Comparison of ribotyping and pulsed-field gel electrophoresis for molecular typing of *Acinetobacter* isolates. *J Clin Microbiol*. 1995;**33**(5):1402-7. [PubMed: 7542274].
- Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, et al. Comparison of outbreak and nonoutbreak *Acinetobacter baumannii* strains by genotypic and phenotypic methods. *J Clin Microbiol*. 1996;**34**(6):1519-25. [PubMed: 8735109].
- Ecker JA, Massire C, Hall TA, Ranken R, Pennella TT, Agasino Ivy C, et al. Identification of *Acinetobacter* species and genotyping of *Acinetobacter baumannii* by multilocus PCR and mass spectrometry. *J Clin Microbiol*. 2006;**44**(8):2921-32. doi: 10.1128/JCM.00619-06. [PubMed: 16891513].
- Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother*. 2001;**45**(12):3375-80. doi: 10.1128/aac.45.12.3375-3380.2001. [PubMed: 11709311].
- Bergogne-Berezin E, Towner KJ. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev*. 1996;**9**(2):148-65. [PubMed: 8964033].
- Ferreira AE, Marchetti DP, Cunha GR, Oliveira LM, Fuentefria DB, Dall Bello AG, et al. Molecular characterization of clinical multidrug-resistant isolates of *Acinetobacter* sp. from hospitals in Porto Alegre, State of Rio Grande do Sul, Brazil. *Rev Soc Bras Med Trop*. 2011;**44**(6):725-30. [PubMed: 22231246].
- Peymani A, Farajnia S, Nahaei MR, Sohrabi N, Abbasi L, Ansarin K, et al. Prevalence of class 1 integron among multidrug-resistant *Acinetobacter baumannii* in Tabriz, northwest of Iran. *Pol J Microbiol*. 2012;**61**(1):57-60. [PubMed: 22708347].
- Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis*. 2008;**61**(4):274-8. [PubMed: 18653968].
- Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant *Acinetobacter* sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. *Antimicrob Agents Chemother*. 2006;**50**(12):4114-23. doi: 10.1128/aac.00778-06. [PubMed: 17000742].